Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Ultragenyx Pharmaceutical Inc. on June 11, 2019. The filing details the voting results for three proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
As of the record date of April 15, 2019, 57,339,027 shares were outstanding. A total of 54,163,035 shares were represented at the meeting. The following proposals were voted upon:
- Proposal 1 (Election of Class III Directors): All three nominees were elected. William Aliski received the highest support with 48,339,981 votes for. Lars Ekman and Matthew K. Fust received approximately 37.7 million and 37.5 million votes for, respectively, with significant votes withheld (over 11 million each).
- Proposal 2 (Ratification of Accounting Firm): Stockholders ratified the selection of Ernst & Young LLP for the fiscal year ending December 31, 2019. The vote was overwhelmingly in favor with 54,071,405 votes for versus 67,929 votes against.
- Proposal 3 (Advisory Vote on Executive Compensation): Stockholders voted in favor of the advisory resolution approving executive compensation. The vote was 33,579,422 for and 15,706,624 against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific reasons for the high number of votes withheld for director nominees Lars Ekman and Matthew K. Fust.
- Review the Proxy Statement referenced in the filing for details on the executive compensation package approved in Proposal 3.
- Confirm the tenure of the newly elected Class III directors, which extends until the 2022 Annual Meeting.